Iambic Therapeutics Announces First Patient Dosed in Phase 1 Clinical Study of IAM1363, a Highly Selective HER2 Inhibitor for the Treatment of Solid Tumors
IAM1363 is the First Program from Iambic’s Leading AI-Driven Drug Discovery Platform to Commence Human Studies SAN DIEGO–(BUSINESS WIRE)–Iambic Therapeutics,…